{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000010","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.663341+00:00","generated_at":"2026-06-19T22:43:32.228851+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiora Pharmaceuticals Receives IND Approval for Phase 2 Study of KIO-101 for Ocular Autoimmune Disease","bullets":["Kiora received IND approval from FDA for Phase 2 study of KIO-101 for ocular surface disease in autoimmune patients.","Phase 2 trial will enroll ~120 patients in a multi-center, randomized, double-masked, controlled study assessing safety and efficacy.","Study expected to begin enrolling patients in Australia in first half of 2023; two concentrations (0.15% and 0.30%) will be tested.","KIO-101 is a topical DHODH inhibitor; systemic DHODH inhibitors generate ~$2B annually; target market ~3.43M U.S. patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000010","json":"https://secwatch.observer/filing/0001372514-23-000010.json","markdown":"https://secwatch.observer/filing/0001372514-23-000010.md","text":"https://secwatch.observer/filing/0001372514-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000010/0001372514-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000010/kprx-20230207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:43:32.228851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}